Cargando…

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8853899/ http://dx.doi.org/10.1007/s40278-022-10135-8

Ejemplares similares

Adalimumab/vedolizumab: Gastroparesis and COVID infection: case report
Publicado: (2021)

Adalimumab/vedolizumab: SARS-CoV-2 infection: 2 case reports
Publicado: (2021)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Mesalazine/tofacitinib/vedolizumab: COVID-19 infection: 3 case reports
Publicado: (2021)

Adalimumab: COVID-19 infection: case report
Publicado: (2022)

The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
por: Chiu, Hsien-Yi, et al.
Publicado: (2015)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Adalimumab/methotrexate: COVID-19 infection: case report
Publicado: (2020)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

Adalimumab: COVID-19 and glomerulosclerosis: case report
Publicado: (2021)

Adalimumab/methotrexate/prednisone: Severe COVID-19 infection: case report
Publicado: (2021)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
por: Okita, Aline Lissa, et al.
Publicado: (2020)

Ustekinumab-induced autoimmune hepatitis: a case report
por: Samah, Ali Said, et al.
Publicado: (2023)

Adalimumab/prednisone: Mycobacterium chelonae infection: case report
Publicado: (2021)

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB
por: Alexander, James L., et al.
Publicado: (2022)

Mercaptopurine/methylprednisolone/ustekinumab: Prolongation of SARS-CoV-2 infection: case report
Publicado: (2020)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Adalimumab/anakinra/dexamethasone: COVID-19 infection, cytomegalovirus reactivation and off-label use: case report
Publicado: (2020)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

A case of ustekinumab-induced sclerouveitis
por: Godwin, Kristen S., et al.
Publicado: (2022)

Ulcerative colitis successfully treated with vedolizumab in the presence of comorbid opportunistic infections: a case report
por: Oki, Yusuke, et al.
Publicado: (2023)

A Case of Evan's Syndrome Induced by Vedolizumab
por: Jen, Henry, et al.
Publicado: (2019)

Adalimumab: Cutaneous leishmaniasis: case report
Publicado: (2022)

Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)

Evaluation of a One-step Dose Reduction Strategy of Adalimumab, Etanercept and Ustekinumab in Patients with Psoriasis in Daily Practice
por: ATALAY, Selma, et al.
Publicado: (2021)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature
por: Sarto, Jordi, et al.
Publicado: (2022)

Vedolizumab-Associated Hypereosinophilia and Hepatoxicity
por: De Marco, Davide, et al.
Publicado: (2022)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Epidermolysis bullosa acquisita treated with ustekinumab: A case report
por: Prosty, Connor, et al.
Publicado: (2022)

Ustekinumab for the treatment of recalcitrant pyoderma gangrenosum: A case report
por: Vallerand, Isabelle A, et al.
Publicado: (2019)

α4β7 Integrin Antagonist Vedolizumab for the Treatment of Refractory Ileitis
por: Filip, Rafał, et al.
Publicado: (2019)

Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
por: Zhang, Zhe, et al.
Publicado: (2022)

Infliximab/vedolizumab: Drug-induced lupus, pneumonitis and lack of efficacy: case report
Publicado: (2021)

Vedolizumab in Crohn’s disease with rectal fistulas and presacral abscess: A case report
por: Yeh, Heng, et al.
Publicado: (2021)

Late Reaction to Ustekinumab Infusion
por: Morais, Marina Resener, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_spm19mr4faka4g11lburk3uf2a